Shilpa Medicare Limited (BOM: 530549)
India
· Delayed Price · Currency is INR | Market Cap | 75.77B |
| Revenue (ttm) | 12.27B |
| Net Income (ttm) | 610.83M |
| Shares Out | 86.80M |
| EPS (ttm) | 6.66 |
| PE Ratio | 131.05 |
| Forward PE | 53.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,357 |
| Open | 830.05 |
| Previous Close | 824.75 |
| Day's Range | 816.00 - 894.50 |
| 52-Week Range | 313.55 - 959.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatini... [Read more]
Financial Performance
Financial StatementsNews
Shilpa Medicare shares jump 3% as CDMO customer secures USFDA Fast Track Designation for GBM Drug
Shilpa Medicare shares jumped more than 3% after its CDMO customer received Fast Track Designation from the US FDA for their investigational drug for Glioblastomaa (GBM). SML offers end-to-end solutio...
Shilpa Medicare shares surge over 2% after arm gets CEP from EDQM for Desmopressin
Shilpa Medicare shares jumped more than 2% in morning trade after its subsidiary Shilpa Pharma Lifesciences Limited received a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin. Shi...
Shilpa Pharma Lifesciences receives CEP for Desmopressin from EDQM
Shilpa Medicare Limited’s subsidiary, Shilpa Pharma Lifesciences Limited, has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM)...
Shilpa Pharma Lifesciences gets certificate of suitability from EDQM for API, Desmopressin
Shilpa Pharma Lifesciences Limited, a subsidiary of Shilpa Medicare Limited, has recently informed exchanges that the company got a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin...
Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as new CEO
Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has appointed Dr. Sridevi Khambhampaty as its new Chief Executive Officer (CEO), effective from September 19, ...
Shilpa Medicare shares rise 4% to after Antique initiates ‘Buy’ rating with target price of ₹1300
Shilpa Medicare’s stock surged by 3.87% to ₹917 on the NSE at 9:22 AM after Antique Stock Broking initiated a ‘Buy’ rating with a target price of ₹1300. The firm cited Shilpa Medicare’s strong formula...
Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection
Following the company’s statement that the U.S. Food and Drug Administration (FDA) has approved its Bortezomib injection under New Drug Application (NDA) 212782, Shilpa Medicare Ltd.’s stock price inc...
Shilpa Medicare surges over 5% on USFDA approval for Bortezomib Injection
Shilpa Medicare Ltd. has seen its stock price surge by 5.1% or ₹37.30 to trade at ₹768.85 on the National Stock Exchange (NSE) following the company’s announcement of receiving U.S. Food and Drug Admi...
Shilpa Medicare gets USFDA approval for Bortezomib Injection
Shilpa Medicare Ltd has recently informed the exchanges that the USFDA has approved its second NDA [505(b)(2)], injectable product, Bortezomib Injection. Bortezomib Injection is approved for subcutane...
Shilpa Medicare reports successful outcome of Phase 3 studies of SMLNUD07 – NorUDCA
Shilpa Medicare has recently announced that it successfully completed phase-3 clinical studies on its novel productSMLNUD07 – Nor Ursodeoxycholic Acid (NorUDCA) tablets, which is likely to change the ...